A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Recruiting

Phase 2

Axatilimab & RuxolitinibA Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Sponsor:

Incyte Corporation

Code:

NCT06388564

Conditions

Chronic Graft-versus-host-disease

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Axatilimab

Ruxolitinib

Corticosteroids

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-20. This information was provided to ClinicalTrials.gov by Incyte Corporation on 2026-03-23.